Cargando…

Structure Based Antibody-Like Peptidomimetics

Biologics such as monoclonal antibodies (mAb) and soluble receptors represent new classes of therapeutic agents for treatment of several diseases. High affinity and high specificity biologics can be utilized for variety of clinical purposes. Monoclonal antibodies have been used as diagnostic agents...

Descripción completa

Detalles Bibliográficos
Autores principales: Murali, Ramachandran, Greene, Mark I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763629/
https://www.ncbi.nlm.nih.gov/pubmed/24288089
http://dx.doi.org/10.3390/ph5020209
_version_ 1782283048452096000
author Murali, Ramachandran
Greene, Mark I.
author_facet Murali, Ramachandran
Greene, Mark I.
author_sort Murali, Ramachandran
collection PubMed
description Biologics such as monoclonal antibodies (mAb) and soluble receptors represent new classes of therapeutic agents for treatment of several diseases. High affinity and high specificity biologics can be utilized for variety of clinical purposes. Monoclonal antibodies have been used as diagnostic agents when coupled with radionuclide, immune modulatory agents or in the treatment of cancers. Among other limitations of using large molecules for therapy the actual cost of biologics has become an issue. There is an effort among chemists and biologists to reduce the size of biologics which includes monoclonal antibodies and receptors without a reduction of biological efficacy. Single chain antibody, camel antibodies, Fv fragments are examples of this type of deconstructive process. Small high-affinity peptides have been identified using phage screening. Our laboratory used a structure-based approach to develop small-size peptidomimetics from the three-dimensional structure of proteins with immunoglobulin folds as exemplified by CD4 and antibodies. Peptides derived either from the receptor or their cognate ligand mimics the functions of the parental macromolecule. These constrained peptides not only provide a platform for developing small molecule drugs, but also provide insight into the atomic features of protein-protein interactions. A general overview of the reduction of monoclonal antibodies to small exocyclic peptide and its prospects as a useful diagnostic and as a drug in the treatment of cancer are discussed.
format Online
Article
Text
id pubmed-3763629
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-37636292013-11-14 Structure Based Antibody-Like Peptidomimetics Murali, Ramachandran Greene, Mark I. Pharmaceuticals (Basel) Review Biologics such as monoclonal antibodies (mAb) and soluble receptors represent new classes of therapeutic agents for treatment of several diseases. High affinity and high specificity biologics can be utilized for variety of clinical purposes. Monoclonal antibodies have been used as diagnostic agents when coupled with radionuclide, immune modulatory agents or in the treatment of cancers. Among other limitations of using large molecules for therapy the actual cost of biologics has become an issue. There is an effort among chemists and biologists to reduce the size of biologics which includes monoclonal antibodies and receptors without a reduction of biological efficacy. Single chain antibody, camel antibodies, Fv fragments are examples of this type of deconstructive process. Small high-affinity peptides have been identified using phage screening. Our laboratory used a structure-based approach to develop small-size peptidomimetics from the three-dimensional structure of proteins with immunoglobulin folds as exemplified by CD4 and antibodies. Peptides derived either from the receptor or their cognate ligand mimics the functions of the parental macromolecule. These constrained peptides not only provide a platform for developing small molecule drugs, but also provide insight into the atomic features of protein-protein interactions. A general overview of the reduction of monoclonal antibodies to small exocyclic peptide and its prospects as a useful diagnostic and as a drug in the treatment of cancer are discussed. MDPI 2012-02-16 /pmc/articles/PMC3763629/ /pubmed/24288089 http://dx.doi.org/10.3390/ph5020209 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Murali, Ramachandran
Greene, Mark I.
Structure Based Antibody-Like Peptidomimetics
title Structure Based Antibody-Like Peptidomimetics
title_full Structure Based Antibody-Like Peptidomimetics
title_fullStr Structure Based Antibody-Like Peptidomimetics
title_full_unstemmed Structure Based Antibody-Like Peptidomimetics
title_short Structure Based Antibody-Like Peptidomimetics
title_sort structure based antibody-like peptidomimetics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763629/
https://www.ncbi.nlm.nih.gov/pubmed/24288089
http://dx.doi.org/10.3390/ph5020209
work_keys_str_mv AT muraliramachandran structurebasedantibodylikepeptidomimetics
AT greenemarki structurebasedantibodylikepeptidomimetics